{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:16:45Z","timestamp":1753892205279,"version":"3.41.2"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"publisher","award":["81770318","82170318","81870244","7192051"],"award-info":[{"award-number":["81770318","82170318","81870244","7192051"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe yet rare inherited arrhythmia disorder. The cornerstone of CPVT medical therapy is the use of \u03b2-blockers; 30% of patients with CPVT do not respond well to optimal \u03b2-blocker treatment. Studies have shown that flecainide effectively prevents life-threatening arrhythmias in CPVT. Flecainide is a class IC antiarrhythmic drug blocking cardiac sodium channels. RyR2 inhibition is proposed as the principal mechanism of antiarrhythmic action of flecainide in CPVT, while it is highly debated. In this article, we review the current progress of this issue.<\/jats:p>","DOI":"10.3389\/fphys.2022.850117","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T10:54:27Z","timestamp":1646823267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia"],"prefix":"10.3389","volume":"13","author":[{"given":"Yukun","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuesi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinmeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changsheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ribo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfei","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1146\/annurev.me.36.020185.002041","article-title":"Digitalis toxicity","volume":"36","author":"Antman","year":"1985","journal-title":"Annu. Rev. Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fcvm.2019.00092","article-title":"CPVT: arrhythmogenesis, therapeutic management, and future perspectives. A brief review of the literature","volume":"6","author":"Baltogiannis","year":"2019","journal-title":"Front. Cardiovasc. Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/bph.13521","article-title":"Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor","volume":"173","author":"Bannister","year":"2016","journal-title":"Brit. J. Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1161\/CIRCRESAHA.116.305347","article-title":"The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2","volume":"116","author":"Bannister","year":"2015","journal-title":"Circ. Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/415198a","article-title":"Cardiac excitation\u2013contraction coupling","volume":"415","author":"Bers","year":"2002","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0196-0644(84)80534-X","article-title":"Magnesium therapy in massive digoxin intoxication","volume":"13","author":"French","year":"1984","journal-title":"Ann. Emerg. Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.yjmcc.2011.07.002","article-title":"Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin","volume":"51","author":"Galimberti","year":"2011","journal-title":"J. Mol. Cell. Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.yjmcc.2009.10.005","article-title":"Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass","volume":"48","author":"Hilliard","year":"2010","journal-title":"J. Mol. Cell. Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1161\/CIRCEP.110.959916","article-title":"Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Hwang","year":"2011","journal-title":"Circ. Arrhythm. Electrophysiol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s42826-021-00102-3","article-title":"A comparative review on heart ion channels, action potentials and electrocardiogram in rodents and human: extrapolation of experimental insights to clinic","volume":"37","author":"Joukar","year":"2021","journal-title":"Lab. Anim. Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1001\/jamacardio.2017.1320","article-title":"Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial","volume":"2","author":"Kannankeril","year":"2017","journal-title":"JAMA Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.hrthm.2013.08.011","article-title":"Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia","volume":"10","author":"Khoury","year":"2013","journal-title":"Heart Rhythm"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/BF00736059","article-title":"Sodium channel-blocking properties of flecainide, a class IC antiarrhythmic drug, in Guinea-pig papillary muscles. An open channel blocker or an inactivated channel blocker","volume":"339","author":"Kojima","year":"1989","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1161\/CIRCRESAHA.120.316819","article-title":"RYR2 channel inhibition is the principal mechanism of Flecainide action in CPVT","volume":"128","author":"Kryshtal","year":"2021","journal-title":"Circ. Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bbrep.2017.01.002","article-title":"Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen-Tawil syndrome-iPS cell-derived cardiomyocytes","volume":"9","author":"Kuroda","year":"2017","journal-title":"Biochem. Biophys. Rep"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1161\/01.cir.91.5.1512","article-title":"Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients","volume":"91","author":"Leenhardt","year":"1995","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1161\/CIRCRESAHA.111.247338","article-title":"Short communication: Flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity","volume":"109","author":"Liu","year":"2011","journal-title":"Circ. Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.tcm.2012.06.008","article-title":"Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia","volume":"22","author":"Liu","year":"2012","journal-title":"Trends Cardiovasc. Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pcad.2007.10.005","article-title":"Catecholaminergic polymorphic ventricular tachycardia","volume":"51","author":"Liu","year":"2008","journal-title":"Prog. Cardiovasc. Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1124\/mol.114.094623","article-title":"Multiple modes of ryanodine receptor 2 inhibition by flecainide","volume":"86","author":"Mehra","year":"2014","journal-title":"Mol. Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.yjmcc.2015.06.021","article-title":"Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide","volume":"86","author":"Melgari","year":"2015","journal-title":"J. Mol. Cell. Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1161\/CIRCEP.113.000170","article-title":"Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate","volume":"6","author":"Miyake","year":"2013","journal-title":"Circ. Arrhythm. Electrophysiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.hrthm.2010.06.032","article-title":"Calcium oscillations and T-wave lability precede ventricular arrhythmias in acquired long QT type 2","volume":"7","author":"N\u011bmec","year":"2010","journal-title":"Heart Rhythm"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e003589","DOI":"10.1161\/CIRCGEN.121.003589","article-title":"Provocation testing and therapeutic response in a newly described channelopathy: RyR2 calcium release deficiency syndrome","volume":"15","author":"Ormerod","year":"2021","journal-title":"Circ. Genom. Precis. Med"},{"key":"ref001","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.hrthm.2015.09.027","article-title":"Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of \u03b2-blockade","volume":"13","author":"Padfield","year":"2016","journal-title":"Heart Rhythm"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1540-8167.2007.00910.x","article-title":"Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome","volume":"19","author":"Pellizz\u00f3n","year":"2008","journal-title":"J. Cardiovasc. Electrophysiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.hrthm.2013.05.014","article-title":"HRS\/EHRA\/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013","volume":"10","author":"Priori","year":"2013","journal-title":"Heart Rhythm"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.hrthm.2021.04.007","article-title":"Flecainide-induced QRS complex widening correlates with negative inotropy","volume":"18","author":"Rab\u00ealo Evangelista","year":"2021","journal-title":"Heart Rhythm"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/cvr\/cvu262","article-title":"Neuronal Na+ channel blockade suppresses arrhythmogenic diastolic Ca2+ release","volume":"106","author":"Radwa\u0144ski","year":"","journal-title":"Cardiovasc. Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/cvr\/cvu262","article-title":"Neuronal Na+ channel blockade suppresses arrhythmogenic diastolic Ca2+ release","volume":"106","author":"Radwa\u0144ski","year":"","journal-title":"Cardiovasc. Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/pace.13569","article-title":"Short-term response to phenytoin sodium in Andersen-Tawil syndrome-1 with a cardiac-dominant phenotype","volume":"42","author":"Rai","year":"2019","journal-title":"Pacing Clin. Electrophysiol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1113\/jphysiol.2004.065003","article-title":"State-dependent trapping of flecainide in the cardiac sodium channel","volume":"560","author":"Ramos","year":"2004","journal-title":"J. Physiol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/mt.2015.93","article-title":"S100A1 DNA-based inotropic therapy protects against proarrhythmogenic ryanodine receptor 2 dysfunction","volume":"23","author":"Ritterhoff","year":"2015","journal-title":"Mol. Ther"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"A37","DOI":"10.1161\/res.115.suppl_1.37","article-title":"Abstract 37: The positive inotropic S100a1 prevents arrhythmogenic sarcoplasmic reticulum Ca2+ leak and ventricular arrhythmias","volume":"115","author":"Ritterhoff","year":"2014","journal-title":"Circ. Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.hrthm.2013.10.027","article-title":"Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia","volume":"11","author":"Roses-Noguer","year":"2014","journal-title":"Heart Rhythm"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1161\/CIRCEP.114.002217","article-title":"Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry","volume":"8","author":"Roston","year":"2015","journal-title":"Circ. Arrhythm. Electrophysiol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jamacardio.2021.4458","article-title":"Clinical and functional characterization of ryanodine receptor 2 variants implicated in calcium-release deficiency syndrome","volume":"7","author":"Roston","year":"2021","journal-title":"JAMA Cardiol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/cells10082101","article-title":"Flecainide paradoxically activates cardiac ryanodine receptor channels under low activity conditions: a potential pro-arrhythmic action","volume":"10","author":"Salvage","year":"2021","journal-title":"Cells"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e0131179","DOI":"10.1371\/journal.pone.0131179","article-title":"Channel activity of cardiac ryanodine receptors (RyR2) determines potency and efficacy of flecainide and R-propafenone against arrhythmogenic calcium waves in ventricular cardiomyocytes","volume":"10","author":"Savio-Galimberti","year":"2015","journal-title":"PLoS One"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/cvr\/cvt012","article-title":"Flecainide reduces Ca2+ spark and wave frequency via inhibition of the sarcolemmal sodium current","volume":"98","author":"Sikkel","year":"2013","journal-title":"Cardiovasc. Res"},{"key":"ref004","first-page":"32","article-title":"Andersen-Tawil syndrome","volume":"6","author":"Smith","year":"2006","journal-title":"Indian Pacing Electrophysiol. J"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCRESAHA.115.306298","article-title":"The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT","volume":"116","author":"Smith","year":"2015","journal-title":"Circ. Res"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jccase.2014.08.009","article-title":"High-dose flecainide with low-dose \u03b2-blocker therapy in catecholaminergic polymorphic ventricular tachycardia: a case report and review of the literature","volume":"11","author":"Steinfurt","year":"2015","journal-title":"J. Cardiol. Cases"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"eaba7287","DOI":"10.1126\/scitranslmed.aba7287","article-title":"Cardiac ryanodine receptor calcium release deficiency syndrome","volume":"13","author":"Sun","year":"2021","journal-title":"Sci. Transl. Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e135952","DOI":"10.1172\/jci.insight.135952","article-title":"Molecular characterization of the calcium release channel deficiency syndrome","volume":"5","author":"Tester","year":"2020","journal-title":"JCI Insight"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00424-010-0820-6","article-title":"Kir 2.1 channelopathies: the Andersen\u2013Tawil syndrome","volume":"460","author":"Tristani-Firouzi","year":"2010","journal-title":"Pflugers Arch. - Eur. J. Physiol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/j.jacc.2011.01.026","article-title":"Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"57","author":"van der Werf","year":"2011","journal-title":"J. Am. Coll. Cardiol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/europace\/eur277","article-title":"Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments","volume":"14","author":"van der Werf","year":"2012","journal-title":"Europace"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.rec.2017.04.032","article-title":"Flecainide reduces ventricular arrhythmias in patients with genotype RyR2-positive catecholaminergic polymorphic ventricular tachycardia","volume":"71","author":"Wang\u00fcemert P\u00e9rez","year":"2018","journal-title":"Rev. Esp. Cardiol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nm.1942","article-title":"Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans","volume":"15","author":"Watanabe","year":"2009","journal-title":"Nat. Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.hrthm.2012.12.035","article-title":"Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia","volume":"10","author":"Watanabe","year":"2013","journal-title":"Heart Rhythm"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1161\/01.RES.85.9.770","article-title":"Ca2+ release mechanisms, Ca2+ Sparks, and local control of excitation-contraction coupling in Normal heart muscle","volume":"85","author":"Wier","year":"1999","journal-title":"Circ. Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1113\/JP276757","article-title":"Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia","volume":"598","author":"Wleklinski","year":"2020","journal-title":"J. Physiol"},{"key":"ref003","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.yjmcc.2021.05.007","article-title":"Mechanisms of flecainide induced negative inotropy: an in silico study","volume":"158","author":"Yang","year":"2021","journal-title":"J. Mol. Cell Cardiol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1113\/JP271282","article-title":"In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia","volume":"594","author":"Yang","year":"2016","journal-title":"J. Physiol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1161\/CIRCULATIONAHA.104.472498","article-title":"Electrocardiographic features in Andersen-Tawil syndrome patients With KCNJ2 mutations","volume":"111","author":"Zhang","year":"2005","journal-title":"Circulation"}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.850117\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T10:54:32Z","timestamp":1646823272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.850117\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":56,"alternative-id":["10.3389\/fphys.2022.850117"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2022.850117","relation":{},"ISSN":["1664-042X"],"issn-type":[{"type":"electronic","value":"1664-042X"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"article-number":"850117"}}